Pathology update - good

It took a while but we finally got a pathology determination on whether the tumor has mutations that are sometimes seen with colon cancer. They are KRAS and BRAF, and both were negative. This means in the future we can use another new medication (if necessary) called Erbitux (a EGFR inhibitor), and not having the BRAF mutation is good because it is a poor prognostic factor.

Both of these are good.